Assessing Subjective Burden in Patients with Atopic Dermatitis
Overview
Melinda Gooderham and Jonathan Silverberg discuss how to assess the subjective burden in patients with AD
This Class for
- Physician
- Resident / Fellow
What I will learn?
Educate about the management of Atopic Dermatitis
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
Please go to PDF Material for prescribing information
PP-LY-SA-0044
Related Classes
- Deep Response to IL‑13 and IL‑4/13 Inhibition in AD
- Role of IL‑13 in Atopic Dermatitis (AD)
- Is FACE/Neck AD Treatable? A Real Patient Case with Dr. Fares Alkhayal
- Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment
- Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights
- Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights
- Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate
- Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD